A new publication in Vaccines suggests the importance of COVID-19 vaccination is not only in preventing the spread of infectious diseases, but also in considering its long-term value in reducing the economic burden of non-communicable diseases such as ischemic stroke after SARS-CoV-2 infection.
The study aimed to explore the cost-effectiveness of the two-dose inactivated COVID-19 vaccination program in reducing the economic burden of ischemic stroke after SARS-CoV-2 infection. Researchers constructed a decision-analytic Markov model to compare the two-dose inactivated COVID-19 vaccination strategy to the no vaccination strategy using cohort simulation, and calculated incremental cost-effectiveness ratios (ICERs) to evaluate the cost-effectiveness and used number of the ischemic stroke cases after SARS-CoV-2 infection and quality-adjusted life-years (QALYs) to assess effects.
The findings showed that the two-dose inactivated vaccination strategy reduced ischemic stroke cases after SARS-CoV-2 infection by 80.89% (127/157) with a USD 1.09 million as vaccination program cost, saved USD 3675.69 million as direct health care costs and gained 26.56 million QALYs compared with no vaccination strategy among 100,000 COVID-19 patients (ICER < 0 per QALY gained).
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.